Files

Download

Download Full Text (2.9 MB)

Description

Psoriasis is a chronic inflammatory skin disease marked by keratinocyte hyperproliferation and immune dysregulation. Verrucous psoriasis, a rare variant, presents with thick, hyperkeratotic, wart-like plaques that are often refractory to standard treatments. Secukinumab, a monoclonal antibody targeting IL-17A, has demonstrated efficacy in plaque psoriasis, but data on its use in verrucous psoriasis is limited. This case highlights complete remission of verrucous psoriasis with secukinumab.

Publication Date

3-13-2025

Keywords

Psoriasis

Disciplines

Dermatology

Comments

2025 Alvin Yarrows Research Day at Corewell Health Hospital Farmington Hills, Farmington Hills, MI, March 13, 2025.

Verrucous Psoriasis Treated with Secukinumab

Share

COinS